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ABSTRACT
Aim:
To  study  the  association  between  plasma  apolipoprotein  B  (apo  B)  and  angiographically  proven 
Coronary Artery Disease (CAD) in a prospective manner.
                                    Background:
The plasma apo B concentration represents the number of atherogenic lipoproteins and it has been 
demonstrated that it could be a predictor for CAD.  This study was done to find out whether apo B is an 
independent risk factor for CAD and whether apo B is superior to routine lipid profile in differentiating 
patient with CAD.
                                 Materials and Methods:
The study population consisted of both men and women who were undergoing their first angiography 
between March 2004 and December 2005.  A total of 200 consecutive patients were enrolled.  Patients 
were divided in to 2 groups; Group 1: Patients with angiographically proved CAD were included.  
Group 2: Patients with normal coronary angiogram or patients with negative stress testing by treadmill. 
After an overnight fasting, blood samples were taken for lipids and apo B.  Baseline characteristics 
such as hypertension, diabetes, and smoking were taken from all the patients.  A patient was said to  
have CAD (CAD+) if there was an angiographic lesion more than 50%.  A patient was considered as  
control (CAD-), if angiogram was normal or treadmill stress testing was negative.
                                             Results:
A total of 200 patients were enrolled. There were 155 males and 45 females in the study. There were 
slightly more number of males in group 1.  The total cholesterol was higher in patients with CAD when 
compared to controls.  When we use the cut off value of 150mg or above as hypertriglyceridemia, then 
52% of CAD patients were found to have higher values compared to controls, which was only 35%. 
For a cut off value of LDL less than 130mg%, it was found that 94% of controls and 83% of patients  
with CAD had lower values. 
The median apo B values in patients with CAD were 1.07g/L, versus in controls 0.79g/L, which was 
statistically significant.  We calculated Receiver Operating Curves (ROC) to assess the sensitivity and 
specificity of apo B in identifying a patient with CAD.  For a cut off value 0.99 g/L, it was found that  
the sensitivity was 66% and specificity was 92%. The area under the curve was 0.814.
                                       Conclusion: 
Our results suggest that apolipoprotein B provides better information regarding the presence of CAD. 
Higher apo B values were noted even in those patients with CAD with normal levels of LDL.  In 
patients who were on statins only apo B was able to predict the presence of CAD.  Apo B is a better 
predictor for CAD than routine LDL levels.
INTRODUCTION 
                 The association between serum cholesterol levels and atherosclerosis in humans was  
suggested  when  Thannhauser  and  Muller  in  1938  demonstrated  familial  aggregation  of 
individuals with tendon xanthomata, hypercholesterolemia, and CAD.1   The association was 
generalized by studies such as those in Framingham, which demonstrated that the risk for 
coronary artery disease rose over the entire range of serum cholesterol.  This relation was seen 
predominantly in those persons 30 to 49 years of age at entry into the study and most markedly 
in those 30 to 39 years old.
Different lipoproteins affect risk differently.   Among subjects 49 years and older, low 
density  lipoprotein  (LDL)  cholesterol  was  associated  with  moderate  CAD  risk  ,  
however  , in these older individuals, the high density lipoprotein (HDL) cholesterol   
level seemed to have  greater inverse predictive value.  2   Decreased  HDL cholesterol  
also was shown to be associated with CAD risk in younger people.  3   And finally,  
elevated triglyceride (TGL) levels have been linked with CAD   4-6    but   may not be  
independent of the effect of other lipoproteins or of obesity.  7 
Alaupovic8 was  the  first  to  suggest  that  apoproteins  should  be  considered  when 
evaluating lipoprotein disorders, and in the early 1970s several groups  9  demonstrated 
elevations in plasma LDL and/or very low-density lipoprotein (VLDL) apo B levels in 
patients with most types of hyperlipidemia. 
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In 1978 Avogaro et al. 1 found that total plasma apo B levels were elevated in individuals 
with  CAD  regardless  of  whether  they  were  normocholesterolemic  or 
hypercholesterolemic.  Vergani et al.10 and others  11-15 also found higher plasma apo B 
levels  in  subjects  with  atherosclerosis  than  those  apparently  free  of  atherosclerosis. 
Indeed, higher plasma apo B levels were reported in persons with CAD compared to 
those without CAD, even in those with normal lipid levels.16
Sniderman et al. 1 measured apo B levels in LDL separated from VLDL by exclusion gel 
radial immunodiffusion or by preparative ultracentrifugation.  Among those with CAD 
diagnosed by angiography with normal LDL cholesterol levels Sniderman et al.  1 noted 
elevated LDL apo B.  They termed this entity, characterized by 1) LDL cholesterol below 
200  mg/dl,  2)  Elevated  LDL  and  apo  B,  3)  Low  LDL  cholesterol/apo  B 
ratio,"hyperapobetalipoproteinemia”.  Apo  B  has  been  shown  in  prospective 
epidemiological  studies to predict  first  Ischemic Heart  Disease (IHD) event  -  Typical 
effort angina, Nonfatal myocardial infarction, and coronary death.  Apo B levels have also 
been shown to predict risk of both recurrent ischemia and death among patients with 
Acute Coronary Syndrome. 
Thus apo B has been proven to be a novel biochemical marker in primary prevention 
setting in predicting future cardiovascular events.  Apo B may be regarded as  a relevant 
tool in the assessment of IHD risk, because it may provide information that would not be 
obtained  from the conventional  lipid-lipoprotein  profile.  17  This  study  was  done  to 
address  the  correlation  between  apo  B  levels  and  coronary  angiographic  findings  in 
patients admitted for elective coronary angiography (CAG). 
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AIMS AND OBJECTIVES
AIM OF THE STUDY:
To determine the presence of an association between apo B and Coronary Artery Disease 
in Indian population.
OBJECTIVES OF THE STUDY:
1. To find  out  whether  apo B is  an independent  risk factor  for  Coronary Artery 
Disease. 
2. To see whether apo B is superior to routine lipid profile in differentiating patients 
with Coronary Artery Disease.
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REVIEW OF LITERATURE
Over 90% of low density lipoprotein (LDL) particle is composed of apo B.  It serves the 
function of solubalizing cholesterol within the LDL complex, which in turn increases the 
transport capacity of LDL for subsequent deposit on the arterial wall.  Apo B is therefore 
a convenient marker for assessing the cholesterol depositing capacity of the blood. 
Apolipoproteins (apoproteins) are a specialized group of proteins that associate with 
lipids and mediate several biochemical steps associated with plasma lipid metabolism. 
The apolipoproteins are designated by letters and Roman numerals, for example, apo A-I 
and apo C – II.  The designations arose from two sources.  First, it was once thought that 
apolipoproteins composed families, so those forming a family were given the same letter 
prefix.  The scheme has remained even though its basis is no longer widely accepted. 
The numbers refer simply to the order in which the fractions that contain them emerge 
from a chromatographic column in their isolations. 
The apolipoproteins encompass a wide range of molecular masses, from less than 6kDa 
for apo C – I to more than 500kDa for some B apolipoproteins and apo [a].  The plasma 
apolipoproteins can be divided in to three groups according to shared protein and gene 
structures.   Apo B-100 and apo B-48 form the group 2 plasma apolipoproteins.  The two 
apolipoproteins are grouped together because they are very large and are associated with 
the cholesteryl ester – rich lipoproteins and TGRLs (TriGlyceride Rich Lipoproteins).
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Apo B-100 also contains several lipid-binding domains.  They have been identified in a 
tryptic digestion, in heparin-binding domains, and in multiple sites of glycosylation.  Apo 
B-100 contains 25 cysteines, some of which are located in a disulfide cluster within the 
first  500 amino acid residues  of the primary structure.   One of the cysteines  form a 
disulfide link with apo [a]; this is the means by which apo [a] is attached to LDL.  Apo B-
48 is the amino terminal 48% of apo B-100.  Although a single gene codes for both 
proteins, mRNA editing machinery in the intestine substitutes a stop codon for one that 
codes for an amino acid (Chen et al. 1987).  Apo B-48 contains some of the glycosylation 
and heparin-binding sites as well as the disulfide cluster of apo B-100, but it does not 
contain  the  receptor-binding  domain  of  apo  B-100  that  targets  LDL to  cell  surface 
receptors.
Although all mature lipoproteins have a uniform surface monolayer of lipoproteins and 
phospholipids, there is considerable heterogeneity in apolipoprotein ratio depending on 
the  metabolic  state  of  the  subject.   Larger  VLDL particles  contain  apo  B-100,  C 
apolipoproteins,  and  apo  E.   Smaller  VLDL particles  contain  less  C  apolipoprotein. 
Virtually the entire protein component of Intermediate Density Lipoprotein (IDL) is apo 
B-100 and apo E.   An LDL particle  contains  one molecule of  apo B-100 as  its  sole 
protein. 18
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Apoproteins  not  only  stabilize  lipoprotein  structure  but  also  have  other  important 
regulatory functions in lipoprotein metabolism.  Apolipoproteins B-100 and E are 
necessary for the binding of lipoproteins to cellular receptors, whereas apoproteins A-I 
and C-II are activators of enzymes important in lipoprotein metabolism.
Apolipoprotein measurements help to determine CAD risk such as apoprotein A-I (the 
major HDL protein) and apolipoprotein B (the major LDL protein).   Measurement of 
apoprotein B may be clinically useful in certain situations.  In a patient with CAD and an 
apparently  normal  cholesterol  concentration,  apo  B  measurement  may  be  high. 
Apolipoprotein  B  is  also  helpful  in  the  assessment  of  CAD  risk  in  the 
hypertriglyceridaemic patient with a relatively normal cholesterol concentration. 19
COMPARISON OF APO B TO OTHER RISK FACTORS:
Although the conventional approach to assessing the risk of CAD and the adequacy of 
therapy remains LDL cholesterol, there is compelling evidence that apo B is superior to 
LDL cholesterol for both of these purposes.  The evidence can be grouped into 6 major 
categories,  each  of  which  is  important,  but  each  of  which  supports  the  others;  and 
therefore,  taken  together,  these  6  categories  of  evidence  lead  to  straightforward  and 
definitive conclusions.
The first major category consists of the studies that demonstrated that increased numbers 
of small, dense LDL are not only common in patients with CAD but, in fact, are much 
more common than increased LDL cholesterol.  
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The second major category of evidence includes the series of metabolic studies that have 
elucidated the metabolic basis for the increased numbers of small, dense LDL, which are 
so  common  in  coronary  patients.   These  studies  have  demonstrated  that  increased 
numbers of small, dense LDL are the result of increased secretion of very low-density 
lipoprotein (VLDL) by the liver.  In addition, they have shown that shifts of cholesterol 
ester and triglyceride between VLDL and LDL and then hydrolysis of triglyceride within 
the LDL are responsible for the changes in composition.
The third category consists of the extensive series of in vitro and in vivo studies that have 
shown that small, dense, cholesterol-depleted LDL particles are more atherogenic than 
LDL particles of normal composition.  
The fourth  category of  evidence includes  the  results  of  recent  major  epidemiological 
studies, which have demonstrated that apo B is a better index of the risk of coronary 
artery disease than LDL cholesterol.  In the cross sectional study by Westerveld et al  20 
where 289 women were followed up for 5 years, apo B was the best discriminant between 
CAD – and CAD +.  Even among women in the lowest quartiles of Total cholesterol, 
LDL-cholesterol, and Triglyceride, who had angiographically proven CAD, apo B was 
significantly higher (See figure 1). 
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Apo B Levels In Lowest Quartiles Of Total Cholesterol, LDL – Cholesterol, Triglycerides And In The 
Highest Quartiles Of HDL – Cholesterol.
Figure 1: This shows plasma concentrations of Apo B (g/L) in the lowest quartiles of plasma cholesterol 
(<5.9 mmol / L), LDL – Cholesterol (< 3.8 mmol / L), and Triglycerides (<1.3 mmol / L) and in the highest 
quartiles of HDL – Cholesterol (> 1.5 mmol / L) in women with (CAD +, black bar) and without (CAD -, 
white bar) angiographically established CAD.  p values were calculated with student’s t test for 
independent samples.20 (TG = Triglycerides)
As  shown  in  figure  1  even  among  patients  with  lowest  levels  of  LDL cholesterol 
(<3.8mmol /  L),  TGL (<1.3mmol  /  L)  and highest  levels  of  HDL cholesterol  (> 1.5 
mmol / L) apo B levels were significantly higher (p = 0.01) in women with CAD + (black 
bar) than in women without CAD (white bar).
 The  Quebec  Cardiovascular  Study  17 was  a  large  prospective  study to  demonstrate 
strongly that apo B was superior to total or LDL cholesterol as an index of vascular risk. 
During  the  five-year  follow-up of  men in  the  Quebec  Cardiovascular  Study,  Kaplan-
Meier survival analysis across tertiles of apolipoprotein (apo) B and A-I levels expressed 
as  the  estimated  probability  for  not  having  ischemic  heart  disease  during  the  5-year 
follow-up suggested that,  men in the third tertile  of  the apo B distribution showed a 
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significant  reduction  in  the  probability of  remaining  free  of  IHD  during  follow-up 
compared with men in the first tertile, whereas the survival probabilities among tertiles of 
apo  A-I  were  not  statistically  different  (P>0.3),  suggesting  that  apo  A-I  may  not 
adequately predict IHD compared to apo B as shown in Figure 2.
Kaplan-Meier Survival Analysis Across Tertiles Of Apolipoprotein (Apo) B And A-I 
Levels
Figure 2: Kaplan-Meier survival analysis across tertiles of apolipoprotein (apo) B and A-I levels expressed  
as the estimated probability for not having ischemic heart disease during the 5-year follow-up of Men in the  
Quebec Cardiovascular Study. 17
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Figure 2 shows that, men in the third tertile of the  apo B distribution had a significant 
reduction in the probability of remaining free of CAD during follow-up compared with 
men in the first tertile.  Whereas such a difference could not be seen across all tertiles  of 
apo A-I , suggesting that apo B is a better predictor of survival probability than apo A-I.
The Apoprotein-related Mortality Risk Study (AMORIS) study  21 is one of the largest 
studies and should be regarded as definitive on the issue of the merits of apo B versus 
LDL  cholesterol,  because  its  specific  objective  was  to  compare  apo  B  and  LDL 
cholesterol,  and standardized,  accurate  methods were used to measure the lipoprotein 
lipids as well as apo B.  In this study, 175,553 Swedes were followed for an average of 
5.5 years.  The clinical event was fatal myocardial infarction.  Apo B was superior to 
LDL cholesterol in every direct comparison.  Although apo B was superior to LDL at 
every level of cholesterol, the difference was particularly marked in those in the lower 
half of the distribution.   
The fifth category of evidence supporting the argument that apo B is superior to LDL 
cholesterol  is  that,  it  is  the  calculation  of  LDL  cholesterol,  which  has  important 
methodological weaknesses, and not the measurement of apo B.  The first weakness is 
that in order to obtain a plasma sample from which LDL cholesterol can be calculated, 
patients must be fasting, whereas they do not need to fast to measure apo B.  Second, it is  
well known that LDL cholesterol cannot be calculated if plasma triglycerides are more 
than 400 mg/dL, and therefore, not infrequently, an estimate of LDL cannot be made. 
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However,  it  is  not  widely  appreciated  that  calculated  LDL  cholesterol  can  differ 
importantly  from  true  LDL cholesterol  in  patients  with  diabetes  mellitus, in  type  3 
dyslipoproteinemia, nephrotic syndrome, and liver disease. 
The  sixth,  and  most  recent,  category  of  evidence  showing  the  importance  of  apo  B 
consists of the series of studies that demonstrate the level of apo B on statin treatment 
remains predictive of outcome, whereas that of LDL cholesterol generally does not.22 - 25. 
This is a major advantage for apo B.  These data indicate that if therapy is guided by apo 
B rather than LDL cholesterol,  statins have a much larger potential  to reduce clinical 
events than is presently being achieved. 
Both LDL and TGRLP (triglyceride-rich lipoproteins) contain apolipoprotein B-100 (apo 
B) as their major  apolipoprotein.  A growing view holds that most, if not all of  apo B 
containing  lipoproteins  are  atherogenic.   Although different  subspecies  of  apo B 
containing lipoproteins may vary in their atherogenic potential, a simplifying concept is 
that most of these subspecies carry similar atherogenicity.  If so, then measurement of 
serum total  apo B signifies the atherogenic potential of the whole lipoprotein fraction. 
Total apo B levels are clearly a strong predictor of CHD risk.  
Total apo B levels correlate relatively strongly with non-HDL cholesterol levels. 23,24  The 
correlation is  particularly strong in  the absence of elevated serum TGL,  but  weakens 
somewhat as TGL levels rise.  Still, non-HDL cholesterol  includes all of the cholesterol in 
apo B-containing  lipoproteins.  Because  there  is  one  apo B molecule  per  lipoprotein 
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particle, total  apo B concentrations  are  a  measure  of  total  particle  number in 
LDL+TGRLP, whereas non-HDL cholesterol provides the cholesterol  content of these 
same lipoproteins.  Whether total  apo B or non-HDL cholesterol is a better predictor of 
CHD risk has not been determined through robust prospective studies.
Non-HDL Cholesterol (or Total Apo B): Replacement for LDL Cholesterol? 
A few investigators 25 propose that non-HDL cholesterol or its correlate, total  apo B, should replace LDL 
cholesterol in clinical cholesterol guidelines.  See Table 1.
Table 1: Treatment Goals for LDL-C, Non-HDL-C, and Total Apo B26
 
Risk Status 
Therapeutic Goal, mg/dL 
Primary  Target: 
LDL Cholesterol 
Secondary  Target: 
Non-HDL 
Cholesterol* 
Secondary  Target:  Total 
Apolipoprotein B  
CHD  and CHD risk 
equivalents||
<100 <130 <90
Multiple  (2+)  risk 
factors
<130 <160 <110
Zero to 1 risk factor <160 <190 <130
*Non-HDL cholesterol becomes a secondary target of therapy when serum triglycerides 
range from 200 to 500 mg/dL.
Apolipoprotein B is an alternate secondary target of therapy when serum triglycerides 
range from 200 to 500 mg/dL.
Includes  a  history of  myocardial  infarction,  unstable  angina,  stable  angina,  coronary 
artery procedures, and clinical evidence of myocardial ischemia.
||Includes  clinical  forms  of  non-coronary  atherosclerotic  vascular  disease  (peripheral 
arterial disease, abdominal aortic aneurysm, clinical carotid artery disease), diabetes, and 
multiple (2 or more) risk factors with 10-year risk for major coronary events (myocardial 
infarction+coronary death) 20%.
Multiple (2 or more) risk factors with 10-year risk for major coronary events 20%. ATP 
III modifies intensity of LDL-lowering therapy required to achieve the goals of therapy 
according to 10-year risk for CHD.
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The table 1 summarizes ATP III’s therapeutic goals for LDL cholesterol and non-HDL cholesterol.  Also 
shown are corresponding goals for total apo B, which are derived from the known relationship between total 
apo B and non-HDL cholesterol. 
Thus total apo B represents an alternative secondary target of therapy. 26 There is growing interest in the 
possibility that additional risk reduction may be obtained by incremental lipid-lowering therapy after ATP 
III’s goals for LDL cholesterol have been met.  If so, the next logical therapeutic target is non-HDL 
cholesterol or total apo B. 
In the study by Tobias Pischon at al 27 both apo B and non–HDL-C have been proposed as markers to reflect 
the  risk  conferred  by  proatherogenic  triglyceride  rich  VLDL in  addition  to  LDL-C.  28,  29 Apo  B was 
associated with increased risk of CAD even after adjustment  for LDL-C or non–HDL-C, despite the high 
degree  of  correlation between  these  variables.   Furthermore,  triglyceride  levels  provided  additional 
information on CHD risk beyond LDL-C and non–HDL-C but not apo B levels.
In the Nurses’ Health Study, 30 apo B was more strongly related to CAD than was LDL-C.  Among persons 
with low non–HDL-C (<139.6  mg/dL)  a  mid-range  level  compared  with  a  low-range  level  of  apo  B 
increased  CAD  risk  by  55%.   This clinical  phenotype,  normocholesterolemic  hyper-apo  B,  has  been 
previously described and hypothesized to have a high risk of  CAD.31  In those with mid-range non–HDL-C 
(139.6 to 171.3 mg/dL), a high compared with a low apo B level increased risk  by & 2.4-fold.  In contrast, 
when apo B was used for the primary risk classification, non–HDL-C levels did not affect risk.
APO B AND CARDIOVASCULAR RISK: EPIDEMIOLOGIC AND CLINICAL 
EVIDENCE:
The  long-term 13-year  follow-up  data  from the  Quebec  Cardiovascular  Study  17 which  evaluated  the 
association between apo B levels and CAD risk indicated that high plasma apo B and LDL cholesterol  
concentrations were  equally and  independently associated with an increased long-term relative  risk of 
CAD.  It was found that high apo B and LDL cholesterol levels are associated with an approximately 2-fold 
increase in the long-term relative risk of CAD after adjustment for nonlipid and lipid variables.  
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Several studies have indicated that increased apo B levels may be associated with a greater risk of CAD  
compared with high LDL cholesterol concentrations. 32,33
In the study by Westerweld et al  20 it was shown that in women undergoing their first 
Coronary angiography, those with lower levels of apo B <0.7 g/L had no CAD whereas 
when the levels of apo B increased there were more women with CAD.  When levels of 
apo  B  were  more  than  2  g/L there  were  no  women  without  CAD as  shown in  the 
following frequency distribution curve (See Figure 3).
Frequency Distributions Of Plasma Apo B Concentrations In Women With And Without CAD.
Figure 3: Frequency distributions of plasma apo B concentrations in women with (CAD+, 
black bar) and without (CAD-, white bar) angiographically established CAD. 20
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In the above figure 3, it is seen that as the levels of apo B increased the frequency of 
patients with CAD increase.  In the group with apo B < 1 g / L there are more CAD –  
patients (white bar) and in the group with apo B > 1 g / L there are more CAD + patients 
(black bar). 
Results from Walldius et al21 showed that apo B had a higher sensitivity and specificity 
than did LDL cholesterol in predicting future coronary death in men and women in the 
Apolipoprotein-related Mortality Risk Study (AMORIS) 21. (See figure 4).  The specific 
aim of the AMORIS study was to compare apo B and LDL cholesterol.  In this study
apo B was superior to LDL at every level of LDL cholesterol, specifically in those with 
lower LDL levels .   
Apo B Versus LDL – Cholesterol In Predicting The Mortality Risk Ratio
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Figure 4: Results in men <70 years from the Apoprotein-Related Mortality Risk Study 
(AMORIS). The risk ratios were calculated after adjustment for cholesterol and 
triglycerides and age.  Apo = apolipoprotein. 21
Figure 4 presents the risk attributable to apo B and apo A1 in men <70 years after the 
effects of cholesterol and triglyceride have been taken into account.  The figure depicts 
the additional substantial predictive power provided by the apoproteins above that 
provided by the lipids.  Note that risk increases both as apo B increases and apo A1 
decreases. 
 Large-scale trials with clinical end points have established that statin therapy decreases 
the risk of CAD events in primary and secondary prevention settings.  However, analysis 
of data of the statin group in the Long-term Intervention with Pravastatin in the Ischemic 
Disease (LIPID) trial showed that levels of apo B after therapy were a better predictor of 
CAD risk compared with LDL cholesterol.
 The  persisting  increased  levels  of  atherogenic  particles  that  were  not  captured  by 
measurement  of  LDL cholesterol  alone  suggests  that  even what  has  been considered 
aggressive  lipid-lowering  therapy  may  not  be  aggressive  enough  to  optimize  risk 
decrease in some patients.  34  This suggests that therapy that focuses not only on LDL 
cholesterol levels but also on apo B concentrations may be useful to more adequately 
decrease the risk of CAD in the general population.
THE POPULATION DISTRIBUTION OF APO B 
 Recently  two  American  studies  have  given  the  distribution  of  apo  B  in  general 
population.  Contois and co-workers  35 presented reference intervals for apo B derived 
from  the  population-based  Framingham  Offspring  Study.   The  mean  (+SD)  apo  B 
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concentration was 1.03 + 0.24 g/L in 1880 men, significantly higher than the mean for 
1944 women (0.96  + 0.26  g/L).   Subjects  with  concentration  of  apo  B greater  than 
1.20g/L were  significantly  more  likely  to  have  CHD (Coronary Heart  Disease)  than 
subjects with apo B concentrations less than 1.00 g/L. 
Bachorik et al.36 measured the concentration of apo B in Phase 1 (1988 –1991) of the 
Third National Health and Nutrition Examination Survey (NHANES III) and found that 
among US civilian population who were 4 years of age or older, apo B concentrations 
were low in childhood (~0.80 g/L) and increasing to ~1.2 g/L in adults.
A large study done in Sweden, with a sample size of 1,47,576 patients the mean value 
(+SD) for apo B was 1.31 + 0.35 g/L in all males and 1.22 +  0.36 g/L in all females.  The 
mean value of apo B increased up to 60 years of age in males and up to 70 years of age in 
females. (See figure 5).
Median Apo B Values In Different Age Groups In Males And Females
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Figure 5: This figure shows the changing apo B levels with increasing age in males and females. 37
As shown in figure 5 in the Swedish study median apo B concentrations in adult males 
increased from 20 – 59 years of age and tended to decrease after the age of 60 years 
whereas  among  females  apo B increased  continuously from 20 –  69  years  and then 
decreased after age 70 
THERAPEUTIC INTERVENTIONS
A number of studies have shown the benefit of reducing apo B in patients with CAD. 
These trials included life style modifications and pharmacological interventions mainly 
statins.
BEHAVIOURAL INTERVENTION: 
Weight Loss:
Visceral obesity is frequently associated with high plasma triglycerides and low plasma 
high density lipoprotein-cholesterol (HDL-C), and with high plasma concentrations of 
apolipoprotein  B (apo B)-containing  lipoproteins.   Atherogenic  dyslipidemia  in  these 
patients  may  be  caused  by  a  combination  of  overproduction  of  very  low  density 
lipoprotein (VLDL) apo B-100, decreased catabolism of apo B-containing particles, and 
increased catabolism of HDL-apoA-I particles.  These abnormalities may be consequent 
on a global metabolic effect of insulin resistance.  Weight reduction, increased physical 
activity,  and  moderate  alcohol  intake  are  first-line  therapies  to  improve  lipid 
abnormalities in visceral obesity.  These lifestyle changes can effectively reduce plasma 
triglycerides and low density lipoprotein-cholesterol (LDL-C), and raise HDL-C.  Kinetic 
studies show that in visceral obesity,  weight loss reduces VLDL-apo B secretion and 
reciprocally upregulates LDL-apo B catabolism, probably owing to reduced visceral fat 
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mass, enhanced insulin sensitivity and decreased hepatic lipogenesis. 
Physical Activity
Regular physical activity may favourably moderate the lipid levels.  It has been found that total cholesterol,  
LDL-cholesterol  and  apo  B concentrations were  lower  in  lean  exercisers  than  in  lean  sedentary men, 
suggesting that exercise influences these risk factors.  
Indeed, time spent in vigorous activity has been noted to significantly predict total cholesterol and LDL-
cholesterol.   Leanness  has  been  observed  to  be  associated  with  favourable  levels  of  HDL-C  and 
triglycerides, while exercise was associated with lower levels of total cholesterol, LDL-cholesterol and apo 
B.
Smoking cessation:
Cigarette smoking is an important risk factor for CAD.  The apolipoprotein A-I has been significantly lower 
and apolipoprotein B significantly higher in smokers than non-smokers.  It has also been noted that those  
who  smoked  >  20  cigarettes/day  had  higher  apolipoprotein  B  levels  than  those  who  smoked  <  10 
cigarettes/day and non-smokers.  
The effect of cessation of smoking in reduction of apo B is less clear and larger clinical 
trials are warranted in this aspect.
 Dietary Factors:
Studies on dietary factors known or hypothesized to confer cardio protection or harm and 
inflammatory markers have begun to provide information about their relations, but a clear 
picture  has  not  emerged.   This  section  provides  a  selective  review of  recent  dietary 
findings.
ω3 Fatty Acids:
Observational and intervention studies suggest that fish intake reduces CAD incidence 
and mortality.  Such cardio protection might be explained by an effect of long chain ω3 
polyunsaturated fatty acids found in fish (and certain plant oils). 
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In the study by Laura Calabresi et al  38 Fourteen Familial Combined Hyper Lipidemia 
patients received 4 capsules daily of ω-3 polyunsaturated fatty acid [ω3 FA] concentrate 
providing 1.88 g of eicosapentaenoic acid [EPA] and 1.48 g of docosahexaenoic acid 
[DHA] per day or placebo for 8 weeks in a randomized, double blind, crossover study. 
Plasma triglycerides were 44% lower, and LDL cholesterol and apolipoprotein (apo) B 
were 25% and 7% higher after ω-3 polyunsaturated fatty acid capsules than placebo. 
In  another  similar  study  39 where  14  patients  received  Omacor,  a  drug containing the  n-3  fatty acids 
eicosapentaenoic and docosahexaenoic acid (EPA and DHA), or placebo for 8 weeks in a randomized,  
double blind, crossover study.  Omacor significantly lowered plasma triglycerides and VLDL-cholesterol 
levels,  by  27  and  18%,  respectively.   Total  cholesterol  did  not  change  but  LDL-cholesterol  and 
apolipoprotein B (apo B) concentrations increased by 21 and 6%. 
Results  from  several  small  scaled  randomized  trials  of  omega  3  fatty  acids 
supplementation  are  inconsistent.   Larger  scale  trials  in  higher  risk  populations  are 
warrented.
Low fat low cholesterol diet:
Excess body weight can result in changes in plasma lipids and lipoproteins that increase 
the  risk  of  atherosclerotic  cardiovascular disease  (CVD).   Dietary  carbohydrates, 
especially  simple  sugars,  can  also  promote atherogenic  dyslipidemia,  in  large  part 
because  of  effects  on the  metabolism  of  plasma  triacylglycerol-rich  lipoproteins. 
Reductions in dietary carbohydrate intake in diets are achieved both by reductions in total 
calorie intake and by substitution of protein, fat, or both.  In a study by Ronald M Krauss 
et  al  40  the  effects  of  moderate  reductions  in  carbohydrate intake  on  atherogenic 
dyslipidemia in overweight and mildly obese men was tested.  In addition, the  extent to 
which changes in lipoprotein with reductions in carbohydrate intake are influenced by 
30
variations in saturated fat content was also analyzed. 
 All subjects consumed the basal diet (54% of energy as carbohydrate) for 1 wk, after 
which they were randomly assigned to the basal diet (54% carbohydrate, low saturated fat 
diet)  or  1  of the  3  low-carbohydrate  diets,  which  included  39%  carbohydrate,  low 
saturated fat diet or 26% carbohydrate, low saturated fat diet or 26% carbohydrate, high 
saturated fat diet.
The 26%-carbohydrate, low-saturated-fat diet resulted in reductions from baseline in total 
cholesterol, triacylglycerol, apo B levels.  A lower carbohydrate intake was associated 
with reduced plasma apo B concentrations and a reduced ratio of total cholesterol to HDL. 
With weight loss, there were reductions in major lipid and lipoprotein indicators of CVD 
risk (LDL cholesterol, triacylglycerol, apo B, total: HDL cholesterol, and small,  dense 
LDL).
Vitamins:
Supplementation with vitamin E has beneficial effects on oxidative stress and (surrogate) 
markers of atherosclerotic disease but the results on clinical end-points in general have 
been disappointing.  A recent meta-analysis on this subject concluded that there is no 
indication for routine use of antioxidants in order to improve cardiovascular outcome. 41 
In a prospective, double blind randomised placebo-controlled trial of effects of treatment 
with  atorvastatin  and  α-tocopherol  in  44  clinically  stable,  non-diabetic  patients  on 
dialysis  therapy  on apo B and oxidative stress was analyzed.  42  Assessment of  lipid 
profile and oxidative stress was performed at the start of the study and after 12 weeks of 
treatment.
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Treatment  with  atorvastatin  reduced  total  cholesterol,  triglycerides  (TG),  low-density 
lipoprotein  (LDL)  cholesterol,  apolipoprotein  B (apo B)  and levels  of  oxidized  LDL 
(oxLDL)  with  30-43%.   It  had  no  influence  on  LDL  oxidisability.   Additional 
supplementation with alpha-tocopherol had no effect on lipid profile and oxidized LDL 
levels and apo B, but decreased in vitro LDL oxidisability.  Supplementation of alpha-
tocopherol to atorvastatin had beneficial effects on in vitro LDL oxidisability and might 
therefore be of additional value.  Thus the effects of vitamins on apo B levels have not 
been well established and require larger studies. 
Alcohol use:
The  concentrations  of  HDL  cholesterol,  total  plasma  triglycerides,  apo  B were 
significantly  higher  in the  alcohol abusers  than  the  control  subjects.  43   J.  Michael 
Gaziano et  al  44 examined  the  interrelation  among  alcohol consumption,  plasma 
lipoprotein levels,  and the risk of  myocardial infarction in  340 patients who had had 
myocardial  infarctions and an  equal  number  of  age-  and sex-matched  controls.   He 
observed a significant inverse association  between alcohol consumption  and the risk of 
myocardial infarction (P for trend, <0.001 after control for known coronary risk factors). 
Apolipoproteins A-I and A-II were also positively associated with alcohol consumption (P 
for  trend,  <0.001  for  both  A-I and A-II),  whereas  there  was  no  such  relation  for 
apolipoproteins B and E. 
The effect of alcohol consumption on the concentrations of apolipoproteins was evaluated in a study by 
Ikunosuke Sakurabayashi et al.  45  Even in this study apo B and apo B/apo A-I were significantly higher 
(p<0.001) in women who consumed alcohol  (drinking subjects)  than in women who did not  consume 
alcohol (nondrinking subjects). However, in the total subjects and in the men, no significant difference in 
apo  B  was  detected  between  drinking  and  nondrinking  subjects.   Thus  it  appears  that  alcohol  abuse 
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increases  apolipoprotein  concentrations,  but  moderate  drinking  may  not  influence  apolipoprotein 
concentrations. 
PHARMOCOLOGIC INTERVENTIONS:
Several pharmacological agents with demonstrated cardio protective ability reduce apo B levels.
LIPID MODULATING AGENTS:
Lipid modulating medications reported to affect apo B levels include 3 – hydroxy – 3 – methylglutaryl  
coenzyme A reductase inhibitors ( statins), fibrates and niacin. Of these, the findings for statins are by far  
the most robust.
Statins:
In  the  CARDS  study  46 2838  patients  were  randomized  to  atorvastatin  or  placebo  for  evaluation  of 
effectiveness  and  safety  of  atorvastatin  10 mg  daily  versus  placebo  in  the  primary  prevention  of 
cardiovascular disease (CVD) in patients with type 2 diabetes, LDL cholesterol levels ≤4.14 mmol/L and 
triglycerides  ≤6.78 mmol/L.   The  average  length  of  the  trial  was  3.9 years.   The  apo  B  levels  were 
decreased by 23% in the atorvastatin arm compared to placebo, resulting in 37% decrease in CVD events, 
which was evident after 18 months.
In  the  Atorvastatin  Comparative  Cholesterol  Efficacy  and  Safety  Study  (ACCESS),  47 whereas  LDL 
cholesterol decreased from around the 90th percentile for the population to below the 25th percentile, apo B 
that was also around the 90th percentile was decreased only to around the 50th percentile.  The reason why 
LDL is reduced more than apo B by statins is that because there is a single molecule of apo B in every LDL 
particle, serum apo B concentrations reflect the LDL particle concentration.  So clearly the LDL particle  
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concentration does not decline as much on statin therapy as is suggested by the degree of reduction in LDL 
cholesterol. 
There are two mechanisms of action of statins on apo B: one diminishing apo B by the removal of more  
buoyant LDL and the other shifting the distribution of apo B from smaller denser particles to larger more  
buoyant LDL.  The response of apo B to statins would thus appear to reflect both the decrease in buoyant  
LDL and SD-LDL (Small Dense – LDL).  On the other hand, the decrease in LDL cholesterol reflects more 
closely the effect of statins on more buoyant LDL.  Because it is believed that the SD-LDL constitutes a 
greater risk for atherosclerosis,  monitoring statin therapy with an apo B target  as  opposed to an LDL  
cholesterol target may be a more effective means of optimizing statin therapy.  The association of LDL 
cholesterol with atherosclerosis appears to be the result of chemical modification of the apo B component  
of the LDL particle, allowing it to become a ligand for the scavenger receptors of arterial wall monocyte-
macrophages leading to its rapid uptake and foam cell formation.  It is perhaps therefore not surprising that  
apo B is a better indicator of CAD risk than LDL cholesterol and it is increasingly appealing to monitor 
treatment by measuring apo B, the LDL component most directly involved in atherogenesis.
In  a  16-week  multinational  trial,  48 1993  high-risk  patients  were  randomized  to  rosuvastatin  20  mg, 
atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or simvastatin 40 mg for 8 weeks.  Patients  
either remained on starting treatment or switched to lower or milligram-equivalent doses of Rosuvastatin 
for 8 more weeks.  Achieving an apo B of <90 mg/dL in patients with elevated triglycerides was much 
more  difficult  than  achieving  both  LDL-C  <100  mg/dL and  non–HDL-C  <130  mg/dL.  Conversely,  
achieving an apo B of <90 mg/dL guaranteed achieving the dual LDL-C and non–HDL-C targets. 
Switching from statins that are less effective in reducing LDL-C, particularly when they are approaching  
their maximal dose, to those that are more effective in their lower dose range constitutes an important  
treatment option for optimizing achievement of ATP III goals in high-risk patients.  This trial showed that  
switching  from  the  most  commonly  used  doses  of  atorvastatin  or  simvastatin  to  rosuvastatin  at  the 
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recommended starting dose (10 mg) or optional starting dose (20 mg) led to greater achievement of the  
proposed  apo  B target  in  hypertriglyceridemic  patients.   The  magnitude  of  the  benefit  achieved  with 
switching to rosuvastatin in these high-risk patients is consistent with treatment differences observed in  
comparative trials  of  rosuvastatin  and other  statins  at  commonly used  doses.  49,50    Thus Rosuvastatin 
therapies produces greater reductions in apo B levels compared to atorvastatin or simvastatin. 
Fibrates:
Small trials of varying designs have shown that fibrates may also decrease plasma concentrations of apo B 
in hyperlipidemic patients.  The serum apo B concentration comparatively undergoes only minimal change 
by fibrates. 51  On the other hand, fibrate treatment is associated with substantially decreased Small Dense 
(SD)-LDL.  52,53  The relative lack of change in total serum apo B is thus due to a shift from SD-LDL to 
larger LDL.  The decrease in SD-LDL on fibrates is due to the decrease in CETP (cholesteryl ester transfer  
protein) activity, which they induce probably as a consequence of a decreased pool of circulating VLDL. 54 
The lack of change in serum apo B levels on fibrates clearly does not reflect the decrease in SD-LDL and  
the serum triglyceride response is likely to give a better indication of the probable change in SD-LDL.  It is  
possible that apo AI, because of its inverse relationship with triglycerides and thus with SD-LDL, may,  
when expressed as a ratio with apo B, integrate the information about atherosclerotic risk in patients on  
fibrates, but direct evidence for this is largely lacking at present. 
Niacin:
Data from small trials also suggest that niacin may reduce apo B levels.  In a double-blind study 55 of 146 
men who had apolipoprotein B levels greater than or equal to 125 mg per deciliter, documented coronary 
artery disease, and a family history of vascular disease, with a 2 1/2-year follow up, patients were randomly 
assigned to one of three treatments: lovastatin (20 mg twice a day) and colestipol (10 g three times a day);  
niacin (1 g four times a day) and colestipol (10 g three times a day); or conventional therapy with placebo  
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(or colestipol if the low-density lipoprotein [LDL] cholesterol level was elevated).  The levels of LDL and 
high-density lipoprotein (HDL) cholesterol changed only slightly in the conventional-therapy group, but 
more substantially among patients treated with lovastatin and colestipol or niacin and colestipol.  In the 
conventional-therapy group, 46 percent of the patients had definite lesion progression (and no regression) 
in at least one of nine proximal coronary segments; regression was the only change in 11 percent.  By 
comparison, progression (as the only change) was less frequent among patients who received lovastatin and 
colestipol (21 percent) and those who received niacin and colestipol (25 percent), and regression was more 
frequent. 
Clinical events (death, myocardial infarction, or revascularization for worsening symptoms) occurred in 10 
of 52 patients assigned to conventional therapy, as compared with 3 of 46 assigned to receive lovastatin and 
colestipol and 2 of 48 assigned to receive niacin and colestipol. 
Thus to conclude niacin given with colestipol to patients with apolipoprotein B levels greater than or equal 
to 125 mg per deciliter & documented coronary artery disease, similar to lovastatin with colestipol, in men  
with coronary artery disease who were at high risk for cardiovascular events, reduced the frequency of 
progression  of  coronary  lesions,  increased  the  frequency of  regression,  and  reduced  the  incidence  of 
cardiovascular events. 
APO B AND CARDIOVASCULAR PROGNOSIS IN SECONDARY PREVENTION SETTINGS:
Apo B is predictive of recurrent vascular events among patients with Acute Coronary Syndrome and among 
patients with documented CAD.
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Acute coronary syndromes:
James  P.  Corsetti  et  al  56 analysed  272  post  infarction  patients  without  history  of  diabetes  from the 
Thrombogenic Factors and Recurrent Coronary Events (THROMBO) study.  A proportional hazards model  
applied to dichotomized laboratory parameters demonstrated only apo B as a significant predictor of risk  
for recurrent coronary events in patients with metabolic syndrome with hazard ratio, 1.97 (95% CI; 1.08, 
3.60; P < 0.05).  He concluded that apo B is significantly associated with risk for recurrent coronary events  
in postinfarction patients with metabolic syndrome; and further studies would be needed to recommend the 
routine determination of apo B in these patient groups.
Arthur J. Moss et al 57 during a 4-year period (1994–1998), enrolled 1045 patients after recovery from an 
index myocardial infarction.  Average follow-up period was 26 months. High concentrations of apo B were 
associated with recurrent coronary events in the absence of any identified risk from high concentrations  of 
total cholesterol, LDL cholesterol, lipoprotein (a), or triglycerides.  Small dense lipoprotein particles are 
thought  to  contribute to  the  lipid  core  of  atherosclerotic  plaques  58 and  may be  a factor  driving  the 
atherosclerotic  plaque  to  instability,  with  recurrent  coronary  events  related  to  consequent  plaque 
deterioration.59
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METHODOLOGY
The study was  conducted  in  the  Department  of  Cardiology at  the  Christian  Medical 
College, Vellore.
Inclusion Criteria:
The study population consisted of patients who were admitted to Cardiology wards for 
Coronary Angiography.   The indications for angiography were suspicion of Coronary 
Artery Disease (CAD) or preoperative screening for Coronary Artery Disease in subjects 
with valvular disease.
Exclusion Criteria:
Patients undergoing angiography during hospitalization for acute myocardial infarction or 
acute coronary syndrome were excluded to avoid the influence of these stress situations 
on plasma lipids.
Clinical and Lifestyle Characteristics:
All patients were screened by a thorough history and physical examination.  Baseline 
characteristics  such  as  hypertension,  diabetes  and  smoking  were  taken  from  all  the 
patients in a standard proforma.
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Lipids and Apolipoproteins:
After an overnight fasting, blood samples were taken for lipids and apolipoproteins.  The 
fasting lipid profile was estimated with Hitachi 912 analyzer.  The LDL was calculated 
using  the  formula  of  Friedewald  (Total  Cholesterol  –  [HDL  -  cholesterol]-
[0.45xTriglyceride]).  Apo B was measured using immunoturbidimetric assay using the 
Orion Diagnostica.  The later company is one of the manufacturers that have participated 
in the WHO – Capital IFCC standardization programme. 
Coronary Angiography:
Coronary  angiographies  were  performed  according  to  the  standard  Judkins  
techniques.  A patient was said to have CAD if there was an angiographic  
lesion  more  than  50%  lesion.  A  patient  was  considered  as  control,  if  
angiogram was normal or treadmill stress testing was negative.
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Statistics:
• Baseline characteristics are presented as percentage of mean (Standard Deviation) 
and frequency for discrete variables.
• The  Pearson  correlation  coefficient  was  used  to  analyze  the  presence  of  any 
correlation between apo B level, baseline characteristics and CAD. 
• Presence of an association between various risk factors & apo B with CAD was 
analyzed  using  chi  –  square  test  for  univariate  analysis  and binomial  logistic 
regression for multivariate analysis.
• For all analysis significance was considered at a p value of <0.05.
• Student’s t tests for independent samples were used to analyse differences in apo 
B concentrations between CAD – and CAD + groups.
• Both  univariate  and  multivariate  analysis  were  performed  using  SPSS  for 
Windows, version 11 (SPSS,  Inc.,  Chicago,  Illinios) with the assistance of  an 
experienced biostatistician. 
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RESULTS
Subject Population and demographics:
A total of 200 patients were enrolled who had base line demographic information and a baseline apo B 
level.
1. Baseline Characteristics:
a) Age: The mean age was 53.3 years ranging from 24 years to 78 years. 
The following graph shows the distribution of cases.
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Most patients were more than 40 years reflecting the greater prevalence of risk factors in 
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this age group. 
b) Sex: There were 154 male patients (77%) and 46 female patients (23%). 
SEX
FEMALE
MALE
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2. Risk Factors:
The following table shows the percentage of patients who had various risk factors.
MI – Myocardial Infarction
IHD – Ischemic Heart Disease
The percentage of patients having Low HDL, High TGL and High LDL were 99 (49.5%), 
87 (43.5%) and 23 (11.5%) respectively.
RISK FACTORS FREQUENCY PERCENTAGE
Diabetes Mellitus 82 41%
Hypertension 107 53.5%
H/O Smoking 73 36.5%
Past h/o MI/ACS 27 13.5%
Family h/o IHD 24 12%
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3. Apo B and CAD:
a) The median apo B level in the patients studied was 0.89 g/l with range of 0.11 to 
3.00g/l.
b)  The  following  chart  shows  the  distribution  of  patients  with  low  (<  1  g/l), 
intermediate  (1  to  2 g/l)  and high  (>2 g/l)  apo B levels  among patients  with 
Coronary Artery Disease (CAD).
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c) The  following  chart  shows  the  distribution  of  patients  with  low  (<  1  g/l), 
intermediate (1 to 2 g/l) and high (>2 g/l) apo B levels among patients without 
Coronary Artery Disease (CAD). 
None of the patients in the CAD – group had an apo B value more than 2 g/l.
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d) 64% of patients in the CAD group had apo B levels >1 g/l.whereas only 7% of 
patients in the group without CAD had apo B levels >1 g/l.
CAD + Group
Apo B > 1 g/l
Apo B < 1 g/l
CAD - Group
Apo B > 1 g/l
Apo B < 1 g/l
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4. CAG findings:
 The following chart shows the distribution of patients with CAD according to severity. 
0 = Minor CAD
1 = Single Vessel Disease (SVD)
2 = Double Vessel Disease (DVD)
3 = Triple Vessel Disease (TVD)
Significant involvement of coronary artery was taken as more than 50% stenosis, < 50 % 
stenosis was included in the minor CAD group. 7% had Minor CAD 26% had SVD, 26% 
had DVD and 41% had TVD.
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5. CAD and Traditional Risk Factors:
Association  between  traditional  risk  factors  like  age,  gender,  smoking,  hypertension, 
diabetes  mellitus,  dyslipidemia,  family  history  of  CAD  and  past  history  of  MI  was 
analysed using the chi – square test that is summarized below.
Among the association between risk factors and CAD it was found that apo B was the 
most significant. Age, sex, smoking were also significantly associated with CAD.
The association of Apo B was more significant than LDL, TGL, and HDL.
Risk Factors Pearson Square Value  p value
Age 6.64 <0.025
Sex 13.67 <0.001
Smoking 4.85 <0.05
Hypertension 2.43 <0.20
Diabetes Mellitus 2.07 <0.20
Family h/o CAD 1.71 <0.20
Total Cholesterol (TC) >200 7.79 <0.01
LDL > 130 5.94 <0.025
TGL > 150 5.87 <0.025
HDL < 40 3.38 <0.10
Apo B > 0.995 72.16 <0.001
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6. Lipids and Apo B Levels in the Study Population:
Table showing fasting plasma lipids and lipoproteins in CAD – and CAD + patients as 
assessed by angiography.
CAD + CAD - p value (t – test)
Apo B 1.10 + 0.40 0.76 + 0.18 <0.0001
TC 171.61 + 60.58 157.78 + 35.72 <0.05
TGL 197.16 + 167.27 145.50 + 70.79 <0.005
HDL 40.85 + 11.66 43.12 + 11.09 <0.16
LDL 94.42 + 50.14 88.07 + 28.56 <0.27
Age 55.54 + 8.77 51.06 + 8.79 <0.0001
Fasting plasma concentrations of TC, TGL and Apo B were significantly higher in CAD 
+ patients than in CAD – patients.  CAD + patients were significantly older than CAD – 
patients. 
7. Lipids and Apo B in patients on Statins:
Table showing Fasting lipids and apolipoprotein B in patients on statins classified as 
CAD + and CAD -.
CAD + 
(numbers)
CAD –
(numbers)
 p value (Chi square 
test)
TC > 200mg/dl 14 5 < 1
TGL>150mg/dl 35 16 < 0.20
HDL>40mg/dl 30 21 < 1
LDL>130mg/dl 9 2 < 0.20
Apo B>0.99g/l 44 4 < 0.001
In  patients  on  statins  only apo  B,  but  not  LDL was  able  to  predict  the  presence  of 
underlying CAD. 
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8. Logistic Regression Analysis:
In  multivariate  analysis  using  binary  logistic  regression  only  age,  HDL and  Apo  B 
emerged to be significantly associated with the presence of underlying CAD.
Variables in the Equation
-.035 .023 2.256 1 .133 .966
.001 .004 .032 1 .857 1.001
.065 .030 4.669 1 .031 1.067
.028 .022 1.557 1 .212 1.028
-.062 .018 12.227 1 .000 .940
3.576 1.222 8.569 1 .003 35.729
TC
TGL
HDL
LDL
AGE
Constant
Step
1
a
B S.E. Wald df Sig. Exp(B)
Variable(s) entered on step 1: TC, TGL, HDL, LDL, AGE.a. 
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9. ROC curve (Apo B):
ROC Curve
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ROC analysis revealed that a cut off value of apo B more than or equal to 0.99 g/l has 
66% sensitivity and 92% specificity for detection of underlying CAD.
10.  Among patients with CAD - 63.86% of patients with normal LDL levels had apo B 
values more than 0.99 g/l.
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                          DISCUSSION
Apo B has emerged to be a novel marker of risk in patients with cardiovascular disease.  
Apo B serves as a predictor of future cardiovascular events.  Atherosclerosis is a complex 
series of biological responses to the trapping of an atherogenic particle within the arterial 
wall, not simply a piling up of cholesterol.  Injury to the endothelium, oxidation of the 
apo B and phospholipids as well as the cholesterol within the LDL particle, and uptake of 
LDL by macrophages all trigger a wide, intricate, and damaging series of inflammatory 
and healing responses.   Each atherogenic particle  contains 1 molecule of apo B, and 
therefore plasma apo B represents the total atherogenic particle number29.  In this study 
we report the association between plasma apo B and CAD in patients who were admitted 
for elective coronary angiography.
The  most  prevalent  among  the  traditional  risk  factors  were  hypertension,  diabetes 
mellitus & smoking which are well known to be strong coronary risk factors.  Among the 
traditional  risk factors  age,  gender,  smoking,  total  cholesterol  (TC),  TGL,  LDL were 
found to be significantly correlated with CAD.  The median apo B level among patients 
with CAD was 1.07g/L.  The median value of apo B was higher in patients with CAD 
compared to those without CAD.  Apo B was superior to the traditional lipids - TC, LDL, 
HDL, and TGL in predicting the presence of CAD.
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Among patients on statins, only apo B was able to predict the presence of CAD.  Even in 
the patient population with CAD and normal LDL levels, apo B was able to predict the 
presence of CAD.
The role of apo B as an important risk factor is biologically plausible,60, 61 since plasma 
apo  B  concentrations  reflect  the  number  of  atherogenic lipoprotein  particles.62  The 
atherogenic lipoproteins are LDL, containing predominantly cholesterol, VLDL remnants 
(IDL), and chylomicron remnants, which contain both cholesterol and TGL.  LDL and 
remnant particles each contain 1 molecule of apo B as the structural protein, whereas the 
amount of cholesterol and TGL per particle varies, and with it, the atherogenicity of the 
particle.  Large, Triglyceride (TG)-rich VLDL particles  are not considered atherogenic,63 
whereas  smaller  remnants of  TG-rich  lipoprotein  particles  are  atherogenic.  64  Small, 
dense  LDL  particles  are  more  atherogenic  than  are  LDL  particles  of  normal 
composition.65  Increased  small,  dense  LDL concentrations are  reflected  by  a  more 
pronounced  elevation  of  LDL  apo  B  than of  LDL-chol,  and  this  trend  is  often 
accompanied by elevated plasma TG concentrations.  Total Cholesterol is a constituent of 
both atherogenic,  apo B containing lipoproteins and antiatherogenic,  apo A-containing 
lipoproteins. This  heterogeneity  of  lipoprotein  particle  composition  can  explain the 
superiority of apo B over TC and TGL as a CAD risk factor. 
In our study apo B was the best discriminant between CAD + and non-CAD patients. 
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Other  studies  have  shown  that  the predictive  power  of  apo  B  can  be  increased  by 
separation of the plasma into different apo B containing lipoprotein fractions.  The fasting 
remnant, or IDL fraction, was superior to the LDL fraction in predicting the presence66 or 
severity67 of CAD in women with premature CAD.  Postprandial chylomicron remnant 
concentrations were  higher  in  CAD+ than  in  CAD-  patients  while  LDL apo  B  was 
similar.68 IDL-cholesterol was also related to the progression of CAD in a combined group 
of  men  and  women (n=63)  with  premature  CAD.  69  Thus,  parameters  for  remanant 
particles are potentially better CAD risk indicators than is plasma apo B.
Our results suggest that apo B is a better predictor of CAD than traditional lipid profile 
especially on patients with statin treatment.  To the best of our knowledge this is the first 
Indian study to show the same.  Higher apo B values were noted in patients with CAD 
and normal levels of LDL – C as well.  Thus apo B is a better marker than routine lipid 
profile to be used both in general as well as CAD population.
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LIMITATIONS
1. The numbers of patients studied were small and so the study was not adequately 
powered to pick up certain associations. The fact that established risk factors like 
diabetes mellitus was not significantly related to CAD could have been partly 
related to small numbers.
2. Quantification  of  coronary  angiographic  findings  was  limited  to  the  visual 
interpretation, though this is representative of “real world” practice.
3. Only patients with clinically suspected CAD were included in the study. Hence 
the cut off value of apo B as predicted by ROC analysis may not be applicable for  
the general population.
4. Eventhough  coronary  angiography  was  analysed  in  the  present  study,  the 
outcomes of adverse cardiovascular events and mortality were not studied.
5. Our  controls  were  selected  from  treadmill  negative  group.  Treadmill  testing 
cannot establish reliably that these patients had normal coronary angiogram.  
55
CONCLUSION
1. Apolipoprotein B levels provide better information regarding the presence 
of Coronary Artery Disease. 
2. Higher apo B values were noted even in those patients with CAD with 
normal levels of LDL Cholesterol. 
3.  In  patients  who  were  on  statins,  only  apo B  was  able  to  predict  the 
presence of Coronary Artery Disease. 
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ABBREVATIONS AND ACRONYMS
Apo B - Apolipoprotein B
Apo [a] - Apolipoprotein A
Apo C - Apolipoprotein C
CAD - Coronary Artery Disease
CHD - Coronary Heart Disease
IHD - Ischemic Heart Disease
LDL - Low Density Lipoprotein
HDL - High Density Lipoprotein
TGL - Triglycerides
TC - Total Cholesterol
VLDL - Very Low Density Lipoprotein
IDL - Intermediate Density Lipoprotein
CAG - Coronary Angiography
KDa - KiloDaltons
TGRL - Triglyceride Rich Lipoproteins
SVD - Single Vessel Disease
DVD - Double Vessel Disease
TVD - Triple Vessel Disease
S.NO -  Serial Number
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HOSP. NO -  Hospital Number
TMT -  TreadMill Test
DM -  Diabetes Mellitus
H - Hypertension
S -  Smoking
DL -  Dyslipidemia
F -  Family History of CAD
M - Old Myocardial Infarction
PO - Positive
NE - Negative
NO - Not Done
INCO - Inconclusive
M - Male
F - Female
S - Single vessel disease
D - Double vessel disease
T - Triple vessel disease
M - Minor coronary artery Disease
N - Normal coronaries
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PROFORMA
S.No:
Hosp. No.
Name
Age :
Sex :M / F
Address :    
Typical chest pain: Class I / II / III / IV / No
Dyspnea: Class I / II / III / IV / No 
Other symptoms: 
Diabetes Mellitus 1. Yes 2. No 
Hypertension 1. Yes 2. No
Smoking 1. Yes 2. No
Dyslipidemia 1. Yes 2. No
Family h/o of IHD 1. Yes 2. No
Past h/o of MI 1. Yes 2. No
Lipids: TC: TGL: HDL: LDL:
TMT:   Positive / Negative / Inconclusive / No
CAD:   SVD / DVD / TVD / Minor / No
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 APO – B level: 
STUDY DATA
S.No Name H.NO APO - B Age Sex CAD TC TGL HDL LDL TMT Risk factors Statins
1 Minati Sen 447040C 0.65 57 F D 188 111 59 107 NO DM YES
2 Lila Karna 455104C 0.46 49 F N 140 94 50 71 NE DM NO
3 Naresh Kumar 778887B 0.71 61 M S 161 202 27 94 NE DM, H, S, DL, F YES
4 Aijt Kumar Saha 422157C 0.96 55 M S 162 182 43 83 PO DM, H, DL YES
5 Ratan Kumar 455789C 1.02 52 M D 141 102 34 87 PO S NO
6 Subramanian. K 910228A 0.86 58 M T 113 100 38 55 PO H, DL, F, M YES
7 Prabhat Nalini 081726A 0.94 47 F N 161 148 40 91 NO DM, H NO
8 Subash Saha 456784C 1.05 44 M T 116 113 35 58 PO F, M, S YES
9 Muthusamy . P 453112C 1.2 57 M T 141 131 31 84 PO S, M YES
10 Matur Rahman 456392C 1.54 54 M T 114 360 32 10 NO DM, H, FH, M YES
11 Gita Mukerjee 457222C 0.84 54 F N 185 199 40 105 PO D NO
12 Ramaswamy. 001538C 0.83 66 M T 203 154 36 136 PO H,M NO
13 Shyam Sundar 451124C 1.85 45 M T 146 289 39 51 PO DM,S,DL,M YES
14 Pravin Chandra 549534B 0.74 56 M T 202 119 43 135 PO H,S,M NO
15 Chunilal Kanjilal 455251C 0.8 48 M N 127 156 35 61 PO H,S YES
16 Saroj Samantha 514805C 0.71 68 M N 145 56 64 70 NO N NO
17 Gopi Mohan Paul 456310C 0.99 57 M M 147 195 28 80 NO H,S YES
18 Mani 457752C 2 61 M S 147 178 36 75 PO H YES
19 Shankar Sharma 458139C 2.41 50 M S 137 132 37 74 NE H,S YES
20 Swapan Chakrabortty 456865C 0.59 49 M T 214 151 52 132 PO DM,S,DL NO
21 Francis D'costa 457416C 0.81 67 M T 167 182 33 98 NO H NO
22 Vimal Kejriwal 456044C 1.03 52 M D 123 171 33 56 NE S NO
23 Annamma Varghese 458525C 0.9 54 F N 248 110 58 168 NE DM,H,DL,FH NO
24 Kulanthai Raj 518288C 0.85 48 M N 169 214 62 64 NO H,DL NO
25 Niranjan Sadhukhan 458478C 0.87 68 M D 124 216 32 49 NO DM,H,F,M YES
26 Bholanath Pandey 457126C 1.09 59 M S 157 82 45 96 NE M YES
27 Kalawati Mandal 457753C 0.84 47 F N 161 148 48 83 INCON DM,H NO
28 Rahima Bee 739344A 0.74 48 F M 188 95 41 128 NE DM,H,DL,F,M YES
29 Naranath Hyderaly 454478C 1.03 61 M M 205 160 126 47 PO N YES
30 Biswadeb Sarkar 458488C 0.99 42 M N 185 133 116 92 PO S NO
31 Joseph Xavier 449631C 0.7 52 M D 123 105 40 62 NO S YES
32 Embrose 042582A 1.09 53 M T 159 293 39 61 NO DM,F YES
33 Madan Mohan 448575C 0.56 64 M D 113 73 44 54 NO N NO
34 Pradip Kumar Garai 459099C 0.93 48 M T 182 221 36 102 NO H NO
35 Jeevanandan.M 286507C 0.62 54 M N 120 126 39 56 PO H NO
36 Bijay Kanta Dey 428335C 1.08 65 M S 166 123 50 91 PO DM,H,S NO
37 Rabindra Kumar Dash 143683C 0.41 59 M M 213 118 39 150 NE H,S,DL NO
38 Ram Chandra Das 460168C 1.2 49 M D 127 116 41 63 NE S,F YES
39 Maya Saha 925717B 1.14 56 F D 151 142 35 68 PO H,DL YES
40 Ramendra Gopal Sen 138117C 1.45 58 M D 170 90 49 102 NO N NO
41 Sujit Sarkar 457721C 1.05 49 M T 120 206 49 30 PO H,S,DL,F,M YES
42 Brajbahari Sharma 936034B 0.99 57 M T 131 226 35 51 PO DM,H,DL,M YES
43 Prahlad Chandra Sark 459645C 0.96 45 M N 181 287 48 76 PO DM,H,DL NO
44 Sisir Kumar Nayak 441710C 1.02 49 M D 140 120 39 77 PO DM,S,DL,M NO
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45 A.Aandi 158702B 0.89 62 M T 136 81 37 83 PO H,S,DL YES
46 Pradyut Kumar Das 460247C 0.8 56 M S 131 145 35 67 NO DL YES
47 Rameshwar 442317C 0.9 43 M D 112 119 34 54 NO H,DL NO
48 Prawn Krishna 503067C 0.78 59 M T 226 84 65 144 NO DM,H,S,DL,F,M NO
49 Abdul Mumith 459773C 1.3 55 M D 183 120 39 120 PO DM,S,DL,M NO
50 Lalchuni Devi 391545C 0.49 63 F M 145 140 51 66 NO DM,H,DL YES
51 Swarna Kumari 419682C 0.62 44 F N 204 53 58 135 NO N NO
52 Sreenivas Rao 432371C 0.68 67 M T 170 119 35 111 NO DM,H,DL NO
53 Nirmal Sen Gupta 454759C 0.69 62 M D 178 108 37 119 NO DM,H,DL YES
54 Lawan Kumar 455133C 0.75 50 M D 101 79 39 46 PO DM,H YES
55 Kalidas Chowdhury 454717C 0.84 56 M M 189 350 47 72 INCON S,DL YES
56 Hem Borkakoty 393859C 0.66 49 M M 88 106 24 43 NO DM,H NO
57 Shis Pal Singh 453791C 1.2 32 M S 134 93 30 85 NO M NO
58 Byomkesh Das 359814C 1.03 62 M S 237 549 48 79 NO H,S NO
59 Rajammal 702081A 1.31 65 F T 211 109 46 143 PO DM,H,DL NO
60 Lakshmipathy. A 440821C 1.04 53 M T 249 264 49 147 PO DM NO
61 Raj Kishore Prasad 357185C 0.77 55 M D 153 149 39 84 NE H,S,DL NO
62 Samuel *004490 0.61 73 M T 125 111 35 68 PO DM,H,DL,F YES
63 Basanthi Sinha 465133C 0.54 53 F N 153 117 49 87 PO H NO
64 subramaniam.v 473315C 1.67 48 M D 137 125 38 74 PO DM,H,S YES
65 Arumugam 473030C 2.5 24 M T 263 312 41 160 NO DM,H,S,DL,M YES
66 Sivagnanam.V.K 462335C 0.98 71 M T 123 199 35 48 NO H,DL NO
67 Thansangh 678226C 0.71 58 M N 177 160 64 44 NE DM,H NO
68 Shankar Lal 552638C 0.8 57 M M 178 148 52 96 NO S NO
69 Shyamala sarkar 482138C 0.64 42 F T 162 169 42 86 PO H,M YES
70 Nagarajan ramdoss 422882C 0.55 52 M D 168 277 48 65 NO H YES
71 Roshan Ali 677567C 0.79 48 M N 147 124 37 94 NE F YES
72 shir shir kumar 486663C 1.3 55 M T 195 239 36 111 NO H,S,DL NO
73 Shet Sonwani 489238C 1.06 52 M S 102 248 15 37 PO DM,H,S,DL YES
74 Munirathinam 093536A 0.63 73 M S 127 73 37 75 NO DM, S, M YES
75 Jeremiah 205001 0.97 67 M S 153 120 38 91 NO DM,H NO
76 Gordai Bauri 680071C 0.86 50 M N 151 134 43 93 NE H,S,DL,F,M YES
77 Ram Nandan Singh 228177B 0.51 71 M D 103 64 42 48 NO N YES
78 Muthusamy.R 029907C 1.3 60 M M 164 79 56 92 NO H YES
79 Janardan Karmakar 551263C 1.61 51 M T 242 240 44 150 NO H,S YES
80 Hari Barman 513788C 0.8 37 M N 211 116 58 130 NO F NO
81 Renu Bala 533033C 0.57 64 F T 105 130 39 46 NO DM,H,F NO
82 Sachin Kumar Hazra 546860C 0.98 47 M N 195 219 48 104 NE H,S,M YES
83 Alok Ghosh 660765B 0.57 48 M N 185 122 49 112 NO H NO
84 Chandra Pon Mudhi 506621C 1.13 55 F N 206 197 54 113 PO DM,H,DL,F YES
85 Karimunisse 722359A 1.36 47 F D 197 218 45 108 PO DM,DL NO
86 Umeshwar 503773C 1.01 50 M T 134 174 45 54 PO DM,S,DL,F NO
87 Rabindra Nath 548632C 1.04 51 M M 195 145 35 125 PO H,S YES
88 Kisun Viswa Karma 549030C 0.66 58 M M 123 157 34 58 NO DM,H,S,DL YES
89 Alli Rani 119662 0.62 36 F N 172 99 44 108 NE N NO
90 Durgapada Roy 558764C 1.05 52 M S 168 103 46 101 NO S,F,M YES
91 Shaik Zahiruddin 793672B 1.01 48 M T 70 123 17 28 NO H,S,M NO
92 Narayan Singh 236874C 0.63 62 M T 92 110 28 42 NO H,S,DL YES
93 Ramjay Rawani 523612C 1.12 55 M S 153 139 42 83 PO DM,H,S YES
94 Budhu Lal Dey 492137C 0.91 46 M N 151 235 42 62 NO H,S,DL NO
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95 Naresh Prasad Yadav 474418C 0.61 56 M N 177 178 41 100 NO DM,H,S,M YES
96 Ashok Chowdhury 539301C 0.49 63 M M 123 122 36 63 NO H,S YES
97 Fulmati Devi 440404C 0.87 53 F N 176 162 44 100 NO DM,H NO
98 Nand Kishore Thakur 535549C 1.18 58 M S 120 225 45 30 NE DM YES
99 Sujatha Balachandran 090141A 1.08 51 F S 164 148 41 93 NE S YES
100 Shankar 529193C 0.65 58 M N 85 100 35 50 NE N YES
101 Unnithan 510651C 0.74 56 M N 173 128 42 105 NO H NO
102 Randhir Prasad 477823C 1.58 69 M D 152 79 54 82 NO H YES
103 Shruti Devi 563895C 0.95 53 M D 230 410 43 105 NO DM,H,M YES
104 Sudha Ranjan 571009C 1.53 64 M M 124 94 35 70 NE H,S NO
105 Rama Ranjan 002485C 0.89 39 M N 80 77 28 37 NO S NO
106 Ghana Shyam 578308C 1.05 40 M T 172 195 42 91 NE DM,H YES
107 Jacob. P. I 572268C 1.04 45 M D 202 67 39 150 PO H,M NO
108 Ekambaram 339092B 1.2 65 M T 146 182 30 80 NO H,S,M NO
109 Venkatesaperumal 655938A 1.3 65 M D 248 255 58 139 NO DM,H YES
110 Maya Thakur 591011C 0.89 55 F N 211 234 49 156 NO H NO
111 Sundaresan 701287A 0.83 78 M M 118 81 30 72 NO S YES
112 Sumati Ghosh 591993C 0.7 55 F N 182 139 42 112 PO H YES
113 Shahajan Begam 614037C 0.71 43 F N 138 123 35 81 NO N NO
114 Ranu Sengupta 603686C 0.63 50 F N 139 127 49 73 NO N NO
115 Moni Ghosh 610159C 0.71 39 F M 180 139 47 105 NO DM, H, DL YES
116 Nisith 052748c 0.92 63 M N 126 156 41 54 NE H, S, DL YES
117 Subash Chandra 370534C 1.11 65 M S 194 237 48 118 NO DM, H, DL YES
118 Dilip Kumar 615714C 1.11 49 M T 206 276 50 110 NO DM, H, DL NO
119 Ashish Kumar 675369A 0.76 43 M N 134 94 41 74 NO N NO
120 Rita Devi 530820C 0.85 51 F M 162 187 43 86 NO DM, DL YES
121 Ramani Mohan Debnath 616382C 0.95 75 M N 179 215 48 104 NO H, S NO
122 Tapas Kumar.B 618545C 0.84 48 M N 136 120 36 83 NO S NO
123 Mohanam 587470C 1.21 55 M T 566 381 55 435 NO DM, DL YES
124 Shankar Singh 529183C 0.65 56 M N 88 103 33 49 NO DM, S, H, DL YES
125 James Thilagar 562664C 2.01 53 M D 180 285 43 92 NO DM, DL YES
126 Ran Sebak Shaw 949773B 1.06 53 M T 196 447 40 67 PO H, DM, S, FH, DL NO
127 Azeez Khan .M 557463C 0.73 46 M N 113 205 30 53 NO S, DL YES
128 Brajanath Dutta 618090C 1.02 52 M D 178 231 41 98 NO DM, H, DL, ES YES
129 Ghana Voli 262613 1.04 60 M T 305 900 50 82 NO DM, DL YES
130 ShivaKumar 591297C 1.2 56 M T 196 243 40 118 NO H, S YES
131 Bichitra Das 620512C 1.03 40 M T 113 85 33 59 PO N YES
132 Tamil Selvi 667381A 0.77 48 F N 155 80 36 99 NO FH NO
133 Achuthan 613903C 0.74 55 M M 151 149 34 94 NO H, S YES
134 Parvatheiswar Rao 606892C 0.82 63 M M 187 389 38 71 NO DM, H NO
135 Saradindu Naaya 622401C 0.68 55 M M 160 200 43 73 PO N NO
136 Yesupatham 125919B 1.06 62 M N 143 246 32 80 NO DM YES
137 Anjali Kamila 625503C 1.24 47 F S 211 219 45 112 NE N YES
138 Subba Lakshmi 049653B 1.23 59 F T 202 213 40 136 NO DM, H, DL YES
139 Susti Rani 626159C 1 57 F N 186 163 35 121 NO H NO
140 Subrata Chakraborty 486159C 1.28 53 M T 241 348 44 145 PO ES NO
141 Kailash Pati 629545C 1.43 60 M T 263 114 43 217 PO H, FH YES
142 Prabir Lal Banerjee 629315C 0.67 53 M N 115 79 41 59 NO N YES
143 Dasan Gnanaraj 478048C 1.13 59 M T 177 172 32 111 NO DM, ES, DL YES
144 TapanKumar Bhuni 629623C 0.53 39 M N 139 137 55 64 NO FH YES
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145 Padmanaban 613965C 0.74 57 M M 192 193 36 123 NO DM, H YES
146 Rathindra Nath Das 629537C 1.36 45 M S 245 131 39 196 NO N YES
147 Praveer Kumar 619308C 0.92 44 M N 104 54 31 60 NO DM, H NO
148 Rabindranath Dutta 631981C 1.09 55 M S 165 172 36 99 NO H, S NO
149 Chandra Kumar 630899C 1.28 58 M M 247 258 45 161 NO DM, H, ES YES
150 Parvathi 277063B 0.72 55 F N 138 202 39 62 NO DM, H YES
151 Bipad Bavan 634926C 1.03 57 M S 174 249 35 94 NO DM, S YES
152 Saresh Biswas 632234C 1.07 59 M S 209 193 41 124 NO N NO
153 Aloke 646527C 0.77 49 M S 138 141 31 86 NE ES, H, DL YES
154 Jerry William 636825C 0.81 35 M S 142 130 36 101 NE DM NO
155 Dipti Rani 663255C 0.8 62 F N 224 148 59 150 NE H, S YES
156 Ajit 692173c 0.82 52 M N 184 247 35 107 NE S NO
157 Kavalagam 656248C 0.95 67 M N 158 129 33 102 NE S NO
158 Swapan Kumar 663122C 0.69 45 M N 118 152 34 57 NE S NO
159 Nirmal 642857C 0.96 46 M N 235 520 50 103 NE DM, H YES
160 Sabitha Chaterjee 930563A 0.75 47 M N 162 72 49 90 NE H, DL NO
161 Raja Kumari 629835C 0.89 55 F N 164 80 55 99 NE DM NO
162 Maidul Islam 664214C 0.53 61 M N 104 144 34 41 NE ES, H YES
163 Md Azad 718987B 0.51 52 M N 87 94 27 42 NE DM,H YES
164 Girija 665973C 0.46 55 F N 122 62 50 48 NE DM YES
165 Mahendra  593556C 0.66 48 M N 113 71 31 68 NE ES NO
166 Chhaya 663886C 0.77 51 F N 130 111 32 77 NE N YES
167 Sabitha cihish 665593C 1.05 64 F S 159 318 38 70 NE H YES
168 Bhavati roy 675395c 1.05 46 F N 184 150 47 103 NE H, FH YES
169 Maya rani ghosh 675745c 1.03 50 F N 194 184 45 115 NE N NO
170 Prabhot 675530c 0.75 62 M N 164 86 49 93 NE DM NO
171 pandian 646209c 0.99 40 M N 181 204 46 102 NE S, DM YES
172 Gobinda 674311c 0.81 49 M N 136 167 33 67 NE DM NO
173 Jiban 676789c 0.81 49 M N 142 156 38 90 NE FH NO
174 Habibor 676673c 0.71 39 M N 151 147 42 88 NE N NO
175 Pranab 676647c 1.02 53 M N 198 159 48 122 NE S NO
176 Manju 677075c 0.56 47 F N 113 64 42 58 NE DM NO
177 Paritosh 593070c 0.65 42 M N 130 72 35 84 NE DM NO
178 Bidhan 677046c 0.98 41 M N 181 135 44 113 NE N NO
179 Anant 677121c 0.77 57 M N 170 100 50 87 NE FH NO
180 Akhtaruzzaman 675890C 0.85 38 M N 177 143 32 109 NE S YES
181 Antony 311548b 0.97 60 M N 184 178 53 93 NE DM, H NO
182 Md. Amiruddin 675341c 0.88 45 M N 166 141 40 91 NE N NO
183 Shyama Kumar 676198c 1.07 42 M N 171 265 36 84 NE H NO
184 Asha 677077c 0.77 45 F N 166 79 48 103 NE N NO
185 Chanchalundu 677712C 0.79 63 M N 170 93 48 91 NE S, H YES
186 Tapan Kumar 678011C 0.75 51 M N 166 110 48 83 NE N YES
187 Animesh 588790c 1.07 58 M N 211 177 53 123 NE DM YES
188 Muzubur 677639C 0.99 33 M N 166 88 39 110 NE DM NO
189 Nirpendra nath 679067c 0.11 56 M N 179 97 48 103 NE H NO
190 Chhabi Rani 679741c 0.33 47 F N 88 60 48 27 NE N NO
191 Rajadurai. A 678511c 0.57 48 M N 97 107 29 44 NE S YES
192 Saraswati 557176C 3 51 F D 283 1409 34 98 NO DM YES
193 Anil Kumar 451632C 1 63 M T 154 155 48 91 NO N YES
194 Kalipada Saha 614722C 1 74 M S 211 151 46 142 NO N YES
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195 Golak 120175C 1.07 55 M S 159 141 33 98 NO ES YES
196 Raja 672430B 0.52 37 M M 222 164 36 153 NO DM,H,S,M YES
197 InderJit Singh 569591C 0.74 38 M N 86 142 36 27 PO H,DL NO
198 Dipankar 066287c 0.71 37 M N 155 115 43 99 NE ES NO
199 Susheela 776812b 0.65 61 F N 132 71 40 82 NE N NO
200 Bijoy Kumar 694144c 0.7 55 F N 130 160 36 67 NE H NO
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